Pfizer Files 13D/A Amendment for Haleon plc

TL;DR

Pfizer updated its Haleon stake filing (13D/A #8) - ownership changes continue.

AI Summary

Pfizer Inc. filed an amendment (No. 8) to its Schedule 13D on July 29, 2024, regarding its holdings in Haleon plc. The filing indicates a change in the reporting person's beneficial ownership, though specific share counts or dollar values are not detailed in this excerpt. This amendment continues Pfizer's ongoing reporting obligations related to its stake in the consumer healthcare company, Haleon plc.

Why It Matters

This filing is an update to Pfizer's disclosure of its stake in Haleon plc, a significant consumer healthcare company, indicating ongoing changes in beneficial ownership that investors should monitor.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can signal shifts in major shareholder strategy, potentially impacting stock price.

Key Players & Entities

• Pfizer Inc. (company) — Reporting Person
• Haleon plc (company) — Subject Company
• 20240729 (date) — Filing Date

FAQ

Filing Documents

• sch13da-july2024.htm (SC 13D/A) — 56KB
• exh99172024.htm (EX-99.1) — 101KB
• 0000078003-24-000153.txt ( ) — 159KB

Identity and Background

Item 2. Identity and Background. The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule I in its entirety and replacing it with Schedule I attached.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

of the Schedule 13D is hereby supplemented as follows

Item 6 of the Schedule 13D is hereby supplemented as follows July 2024 Share Purchase Deed On July 29, 2024, Pfizer and the Issuer entered into a share purchase deed (the " July 2024 Share Purchase Deed ") providing a framework for the Issuer to make certain off-market purchases of Ordinary Shares from Pfizer (or its nominees) on such number of occasions as Pfizer and the Issuer may agree either in conjunction with any future offer or sale of Ordinary Shares by Pfizer (or its nominees) (excluding, for the avoidance of doubt, any sale of Ordinary Shares to the Issuer pursuant to the July 2024 Share Purchase Deed) or by way of one or more standalone purchases by the Issuer from Pfizer (or its nominees). Off-market purchases consummated under the July 2024 Share Purchase Deed will take place at such prices, in such numbers and otherwise on the terms and conditions set forth in the July Share Purchase Deed and in certain notices contemplated thereby. The July 2024 Share Purchase Deed does not obligate either party to purchase or sell any Ordinary Shares and, in furtherance thereof, provides that either Pfizer or the Issuer (acting in its absolute discretion) may decline to participate in any proposed off-market purchase, in each case, subject to the terms and conditions set forth therein. Assuming the July 2024 Share Purchase Deed is not otherwise terminated in accordance with its terms, the term of the July 2024 Share Purchase Deed will continue until such time as the approval of the Issuer's shareholders expires and is not renewed at a subsequent annual general meeting of the Issuer. The foregoing description of the July 2024 Share Purchase Deed does not purport to be complete and is qualified in its entirety by reference to the actual terms of such agreement, which is filed as Exhibit 99.1 to this Amendment No. 8 and is incorporated by reference herein.

Materials to Be Filed as Exhibits

Item 7. Materials to Be Filed as Exhibits. 99.1 Share Purchase Deed, dated as of July 29, 2024, by and between Pfizer and the Issuer.* * Filed herewith. -3- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated July 29, 2024 PFIZER INC. By s Susan Grant Name Susan Grant Assistant Secretary -4- Schedule I Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of Pfizer The business address of each director and executive officer is co Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001. Unless otherwise indicated, each director and executive officer is a citizen of the United States. NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT Albert Bourla, DVM, Ph.D. Chairman and Chief Executive Officer Chairman and Chief Executive Officer, Pfizer. Ronald E. Blaylock Independent Director Founder, Managing Partner of GenNx360 Capital Partners. Susan Desmond-Hellmann, M.D., M.P.H. Independent Director Former Chief Executive Officer of the Bill Melinda Gates Medical Research Institute. Joseph J. Echevarria Independent Director Retired Chief Executive Officer of Deloitte LLP. Scott Gottlieb, M.D. Independent Director Partner, New Enterprise Associates, Inc.'s Healthcare Investment Team and Resident Fellow of the American Enterprise Institute. Helen H. Hobbs, M.D. Independent Director Investigator of the Howard Hughes Medical Institute Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Susan Hockfield, Ph.D. Independent Director Professor of Neuroscience and President Emerita, Massachusetts Institute of Technology. Dan R. Littman, M.D., Ph.D. Independent Director Helen L. and Martin S. Kimmel Pro

View Full Filing

View this SC 13D/A filing on SEC EDGAR